Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 15/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17893277 | 1.00 | PDK1 (0.44) | PDK1HTTTSHRKDM4EALDH1A1 | |
| SCHEMBL27603051 | 0.85 | KDM4E (0.37) | PDK1KDM4EALDH1A1 | |
| SCHEMBL8425994 | 0.85 | PDK1 (0.48) | PDK1HTTTSHR | |
| SCHEMBL22167698 | 0.84 | PDK1 (0.43) | PDK1ALDH1A1L3MBTL1 | |
| SCHEMBL20671837 | 0.84 | PDK1 (0.43) | PDK1ALDH1A1L3MBTL1 | |
| SCHEMBL3029708 | 0.83 | PDK1 (0.61) | PDK1L3MBTL1 | |
| SCHEMBL2934637 | 0.83 | PDK1 (0.61) | PDK1L3MBTL1 | |
| SCHEMBL571075 | 0.83 | PDK1 (0.61) | PDK1L3MBTL1 | |
| SCHEMBL571192 | 0.82 | PDK1 (0.40) | PDK1HTTKDM4EALDH1A1 | |
| SCHEMBL23361524 | 0.81 | PDK1 (0.42) | PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922426-B | Tetrahydrooxepin pyridine compound | 安斯泰来制药株式会社 | 2021-03-26 | — | — | CN | disclosed |
| EP-3345909-B1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3345909-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9670219-B2 | Tetrahydrooxepinopyridine compound | ASTELLAS PHARMA INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20170050973-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050973-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | CHRNA7, CHRNA5, P2RX7 | PDK1 4566/4885HTT 669/4885TSHR 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.